Effect Of Xuekang Oral Liquid On Prevention And Treatment Of Thrombocytopenia Induced By Chemotherapy Of Non - Small Cell Lung Cancer

Purpose：Lung cancer is currently one of the most common malignant tumor in all over theworld, and the incidence of non-small cell lung cancer (NSCLC) accounts for75%-80%in lung cancer. According to NCCN guidelines shown in non-small cell lungcancer, GP scheme chemotherapy (gemcitabine combined with cisplatin treatment)is now recognized as one of the approaches in the treatment of non-small celllung cancer in domestic and overseas. But in the clinical treatment, theapplication of GP solutions often cause bone marrow suppression, and theinhibition of platelets and neutrophils are more common. Blood kang oral liquid,as a representative drugs of traditional Chinese medicine treatment ofthrombocytopenia, play a unique and important role. Based on non-small cell lungcancer patients who have thrombocytopenia caused by GP after chemotherapy asthe research object to be retrospectively analyzed, through observating andresearching the changes of these patients’the platelet values after applyingblood kang oral liquid, and then summarize the curative effect of the preventionand treatment of thrombocytopenia induced by non-small cell lung cancer GP schemeof chemotherapy. And it will provide other good method of prevention andtreatment of thrombocytopenia induced by non-small cell lung cancer GP programof chemotherapy for clinical.Material and method：1Material:48patients who have common clinical cancer, non-small cell lungcancer were retrospectively summarized and analyzed, and all cases are selectedfrom Liaoning province tumor hospital during the period from December2011toDecember2013, are admitted to hospital data complete non-small cell lung cancer,including26cases with squamous carcinoma,21cases with adenocarcinoma andlarge cell carcinoma in1case. All of the patients’ platelets are less then100×109/L after adopting GP program of chemotherapy, and then the patients weredivided into two groups according to the treatment of thrombocytopenia: The bloodkang group and control group, each group have24patients. In the two groups, patients condition, age and gender have no significant difference, P>0.05, haveno statistical significance and clinical comparability.2Method:2.1Medication methods: All of the patients adopt GP program of chemotherapy:In1,8days given gemcitabine1g/㎡intravenous drip; At the same time, in1-3days given cisplatin25mg/㎡intravenous drip. A periodic solution ofchemotherapy need21days. At least once a week for a routine blood test, whenpatients’platelet is less than100×109/L, blood kang group:24patients useblood kang oral liquid for treatment. Blood kang oral liquid dosage:20ml forevery time, three times a day. And regularly check routine blood, until theplatelet count is normal, discontinued; Control group:24patients as blankcontrol group, they don’t use any antiplatelet agents. If anyone of the patientswho have platelet less than50×109/L, use TPO or IL-11for raising the valueof platelet;less than30×109/L, or significant bleeding tendency, should betreated with platelet transfusion timely.2.2Statistical processing: Analysising and processing all the indicators,include platelet before the treatment, the time of resume normal, platelet valuesafter the treatment and the course of platelet transfusion during the periodthrough statistical software SPSS15.0. Measurement data between groups usingthe mean±standard deviation（x±s）,and using t test to compare, while usingX2test deal with the final inspection and processing of count data between groups,and take P<0.05as the evaluation criteria of statistical differences betweenthe two groups.Results：Before the treatment, the platelet of blood kang group patients is (72.84±22.62）×109/L,and after the treatment, platelet values for blood kang group is（154.85±61.56）×109/L; Before the treatment the platelets of control grouppatients is （69.91±24.18）×109/L，after the treatment, platelet values forcontrol group is（120.13±51.02）×109/L.The platelet value of blood kang group is much higher than that of the control group (P﹤0.05). The control grouppatients with thrombocytopenia in the III degree or above is6cases(accountfor25.0%), among them3patients (account for12.5%)have taken platelettransfusion for5times; While, blood kang group is3cases(account for12.5%),among them1patient (account for4.17%) has taken platelet transfusion for2times. Compared with the control group it is lightly reduced, the differenceis not statistically significant (P﹥0.05).In24patients of blood kang group,2cases have Ⅰdegree of gastrointestinal reaction,2cases have Ⅱdegree ofgastrointestinal reaction, while3of24cases in control group have Ⅱdegreeof gastrointestinal reaction, but it hadn’t effected the treatment.Conclusion：Blood kang oral liquid has the function of treating thrombocytopenia caused bythe GP scheme chemotherapy in non-small cell lung cancer, and because it hasno conflict in application with chemotherapy drugs at the same time, it is goodfor the treatment of patients treated with chemotherapy on time cycle, andenhance treatment adherence. Blood kang oral liquid plays a positive role onreducing the occurrence of severe platelet reduction and the risk of plateletstransfusion. Blood kang oral liquid can improve the patient’s curative effectand the patient’s survival and quality of life to a certain extent. The clinicalapplication of blood kang oral liquid is secure and effective，and it has littleadverse reaction. The price is reasonable, and the benefit crowd is widely.